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1. INTRODUCTION 
The canine lymphoma is a malignant proliferation of lymphocytes that mainly 
affects the lymph nodes, spleen and liver. It represents between roughly a 
7-24% of all the canine’s neoplasias, with an annual incidence of 114/100.000 
individuals. The etiology in this species is consider multifactorial, since it has 
not been identified an etiologic agent isolated.  
2. AIMS 
The main aims are described  next: 
1.  Enumerate the different chemotherapeutic agents used in the treatment 
against the canine lymphoma and understand his action’s mechanism. 
2.  Know the different vaccines against the canine lymphoma that are still 
being developed and his therapeutic target. 
3.  Compare the efficiency of the different therapeutic options indicated in 
the canine lymphoma based on studies made in vivo. 
3. TREATMENTS AGAINST THE CANINE LYMPHOMA  
CHEMOTHERAPY 
In veterinary medicine exists several protocols and combinations of 
chemoterapic drugs. One of the most popular protocol is CHOP which 
combines cyclophosphamide (C), doxorubicin (H for hydroxydaunorubicin), 
vincristine (O for Oncovin) and prednisone (P). 
RADIOTHERAPY 
The radiation of half or whole body has been evaluated as a way to keep the 
remision after doing chemotherapy in canine lymphoma pacients. However, 
the dose of radiation that can be administered safely to the whole body of 
dogs at one time is too low to effectively reduce tumor cell burden.  
IMMUNOTHERAPY 
The immunotherapy is designed to activate cellular components of the 
immune anti-tumoral response or to go directly headed to determinate 
characteristic criticisms of the own tumor.  
Noeadays, there are 2 vaccines that are used like adjuvants of the 
chemotherapy treatment. One of them goes directly against the heat shock 
proteins, specifically Hsp70 and the other one, against the telomerase reverse 
transcriptase (cTERT). 
4. THERAPY EFFICIENCY 
CHEMOTHERAPY 
 
Agents Risk of side efects Average survival time Cost  
Prednisone Low 2 months Very low 
H Moderate 7 months Moderate 
H + C Moderate to High 12-14 months Moderate 
COP Low to Moderate 6 months Moderate 
CHOP Moderate to High 12-14 months Higher 
RADIOTHERAPY 
The radiotherapy is considered a part from chemotherapy. The lymphocytes 
are especially sensitive to this treatment and, besides, does not affect to the 
resistance of the drugs used in the chemotherapy protocol. The TTP (time to 
progresion) and the AST (average survival time) is used to be some 15 and 
others 18 months, respectively. 
Table 1. A brief synopsis of the most common treatment protocols for canine lymphoma	  
6. CONCLUSIONS 
IMMUNOTHERAPY 
Autologous HSPPC-vaccine 
 
Vaccine against the telomerase 
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Fig. 2. TTP and AST of VAC+CHOP and CHOP. The average for all the dogs was 192 days. 
In VAC+CHOP this was significantly longer (209 days) compared with CHOP (85 days). The 
TTP in both groups was an average of 274 days. The average was significantly greater in the 
group of vaccinated (349 days) in front of the no vaccinated (200 days). From Marconato 
(2015). Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-
intense chemotherapy in dogs with advanced indolent B-cell lymphoma 
Fig 3. TTP and AST of VAC+COP and COP. VAC+COP had a TTP longer in comparison 
with COP (160 and 104 days, respectively). The ALS was 290 and 188 days of average, 
respectively. From Peruzzi  et al. (2010). A vaccine targeting telomerase enhances survival of 
dogs affected by B-cell lymphoma 
According to its clinical presentation, the canine lymphoma is classified in 
multicentric, gastrointestinal, mediastinum and extranode; besides  
subclasiffy according to the grade of progression of the disease or the 
presence of clinical symptomatology.  
 
The diagnostic of lymphoma is based on making 
cytology and hystophatology and the precision and 
the sensitivity increase if you make flow cytometry, 
immunohistochemistry or molecular proofs, like 
PCR or PARR (polymerase chain reaction for 
antigen receptorrearrangement), helping to 
differentiate the type of tumoral proliferation.  
1.  Nowadays, the aim of the treatments against canine lymphoma is to increase the time of remision. At the moment, all the treatments are palliative and is 
rarely that they cure the disease. For that reason, we need to focus on other systemic treatment modalities like immunotherapy. 
2.  The autologous HSPPC-vaccine and the vaccine against the cTERT show that, in combination with the chemotherapy, increase the presentation of antigens 
and activate the proliferation of lymphocytes T CD8+ and Natural Killers cells. In this way, they decrease the load tumoral and, thus, delay the relapse and 
prolong the time of survival.  
3.  Actually, the results of the different studies using different and varied protocols of chemotherapy agents, show that it is unlikely the cure of the dogs with 
lymphoma. The immunotherapy can be considered a big strategy to provide an effective therapy without causing toxicity. This represents a significant step 
toward the development of a new class of therapeutics with a more precise and targeted approach to the treatment of canine lympoma. 
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